Another example is a highly selective “monobody” against the active state of cancer-associated KRAS mutants that, when converted to a VHL-based bioPROTAC, selectively degraded the KRAS mutants, providing a more extended suppression of mutant KRAS activity than that achieved by the monobody alone (16). This evidence concerns the gene KRAS and cancer.